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INTRODUCTION 
 
 According to WHO guidelines Gestational diabetes mellitus is 
defined as carbohydrate intolerance of variable severity with onset or first 
recognition during pregnancy. 
 
 It encompasses women whose glucose tolerance will return back to 
normal after pregnancy and those who develop type 2 diabetes with 
persistent glucose intolerence 
 
 Gestational diabetes  affects three to ten percent of pregnant women. 
Due to increased prevalence of obesity and metabolic syndrome, GDM 
incidence increases many fold. Gestational diabetes presents with few 
symptoms and is most commonly picked only by screening .Risks 
associated with GDM are almost the same as those with pre-gestational 
diabetes. But Structural congenital anomalies seen in diabetes complicating 
pregnancy will not present in GDM because women will be normoglycemic 
at the time of conception. 
 
 High frequency of GDM among Indian women needs early diagnosis 
of GDM by means of glucose tolerance test between 24 and 28 week of 
gestational age,  
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 Metzer Et al said that GDM can be found in forty to sixty percent of 
women.  
 
 There are no test available before this gestational age that can predict 
the development of GDM. There is also supportive evidence says that there 
is elevation of serum uric acid in non pregnant patient with diabetes-ADA 
 
 Normally in The first trimester there is elevation of glomerular 
filtration rate and there is decrease in serum uric acid . This is normal 
physiological change. 
 
 In the first trimester, it likely approximates preconception uric acid 
level and elevated levels may identify women who are predisposed to 
metabolic syndrome. This would be useful in predicting GDM at an earlier 
gestational age, thereby aiding in appropriate management of the same to 
prevent maternal and fetal morbidity and mortality. 
 
 Uric acid is the end product of the purine metabolism.it is 
metabolized by kidney. It has antioxidant properties and nearly sixty percent 
of Scavenging of free radicals in human serum is done by uric acid 
 
 The normal value of the serum uric acid is 2.1mg/dL and 7.2mg/dL. 
Normally in The first trimester there is elevation of glomerular filtration 
rate, and the renal plasma flow and there is decrease in serum uric acid. 
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 At term, both are fifty to sixty percent higher than in the non-Pregnant 
state. Increases in blood volume and cardiac Output also seen in pregnancy. 
Increase in RPF and GFR leads to Increased creatinine clearance. Hence 
forty percent of blood urea and serum creatinine reduced (12).  
 
 In non pregnant women uric acid is associated with insulin resistance  
And it is independent risk factor for development of type two diabetes. 
 
 There are two proposed hypothesis by which uric acid can cause 
insulin resistance 
 
 First hypothesis, uric acid causes endothelial dysfunction and 
Decrease nitric oxide production by endothelial cells. Insulin mediates 
Glucose uptake into the cell (adipose tissue and skeletal muscle) depends on 
nitric oxide. Hence decrease in nitric oxide lead to decrease in glucose 
uptake and Development of insulin resistance. 
 
 Another mechanism by which uric acid causes insulin resistance is 
that uric acid causes inflammation and oxidative stress in adipocytes. Which 
contributes to metabolic syndrome in mice. 
 
 Gestational diabetes poses short term as well as long-term effects on 
the health of both the mother and the child. Hence early diagnosis and 
treatment is necessary to decrease the risks. 
Aims & Objectives 
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AIM OF THE STUDY 
 
 TO STUDY THE CORRELATION BETWEEN FIRST TRIMESTER 
URIC ACID CONCENTRATION AND ITS ASSOCIATION WITH 
GESTATIONAL DIABETES. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
GESTATIONAL DIABETES MELLITUS 
 It’s defined as any degree of glucose intolerance with onset or first 
recognition during pregnancy (WHO, ACOG).                
 
 It encompasses women whose glucose tolerance will return back to 
normal after pregnancy and those who develop type 2 diabetes with 
persistent glucose intolerance 
 
PATHOPHYSIOLOGY: 
Effect of insulin on glucose uptake and metabolism. 
 Insulin binds to cell membrane receptor , by binding to  receptor it  
activates many protein cascade ,includes translocation of Glut 4 transporter 
to the plasma membrane and inturn it cause influx of glucose. 
 
 Insulin mediates glycogen formation, glycolysis and fattyacid 
formation. 
 
 Basic Mechanisms behind gestational diabetes remains unknown .As 
we know that insulin resistance is main cause for GDM.  
 
 Insulin action is affected by variety of hormone produced in 
pregnancyas insulin needed for entry of glucose into the cell, because of 
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insulin resistance there is less glucose entry into cells,which leads onto 
increased blood glucose level, To compensate this more insulin is secreted 
in pregnancy 
 
 Insulin resistance is a normally occurs in the second trimester of 
pregnancy, which progress thereafter to levels seen in non pregnant patients 
with type two diabetes. 
 
 Women with GDM have an insulin resistance they cannot compensate 
with increased production in the beta cells of the pancreas.  Placental 
hormones and to a lesser extent increased fat deposits during pregnancy, 
seems to mediate insulin resistance during pregnancy. 
 
 Mainly Cortisol and progesterone , human placental lactogen, 
prolactin and estradiol contribute to lesser extent. 
 
 Even though there is number of explanation its very unclear why 
some patients alone developing GDM. 
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 Pedersen proposed the theory of hyperglycemic- hyperinsulinism.  
According to this maternal hyperglycemia, increased blood glucose in 
mother induces fetal hyperglycemia lead on to fetal pancreatic beta cells 
hypertrophy leading to fetal hyperinsulinemia.  Fetal hyperinsulinemia is 
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responsible for the increased fat deposition and macrosomia, organomegaly,   
increased erythropoietin production and decreased surfactant production.  
As a result fetuses are increased risk of birth trauma and intrapartum 
asphyxia, respiratory distress syndrome and polycythemia in the newborn. 
 
SCREENING AND DIAGNOSIS OF GESTATIONAL DIABETES 
MELLITUS 
 However controversy continues whether we need selective screening 
or universal screening based on risk factors. 
 
 ADA in 1977 recommended that selective screening.    
 
 Women belonging to high risk racial group like Indian warrant 
universal screening.  
 
 ACOG (2011) suggests that universal screening by patient history, 
clinical risk factor, random blood glucose test (at booking visit), oral 
glucose challenge test (24-28 weeks of gestation) . GDM is diagnosed based 
on 100gm 3 hour OGTT (diagnosed as GDM if pt having two or more 
positive values). 
 
 ACOG recommends two step approach, 50gm glucose challenge test 
(O Sullivan test) is performed, if its positive, confirmed by an OGTT. 
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GLUCOSE CHALLENGE TEST: 
 It is done at twenty four to twenty eight weeks. Oral glucose of 50 gm 
is given and Venus blood glucose measured 1 hour later.   
 
 Sensitivity of the test depends on the cut off value of the test.  When 
130 mg is used as the upper limit, the sensitivity of the test is 90 % which 
falls to 80 % if cutoff  limit is increased to 140 mg. Thus, a large number of 
populations subjected to OGTT unnecessarily.  
 
 To overcome the limitations of O’ Sullivan’s test, American Diabetic 
Association (ADA) and the IADPSG (2011) recommended one step 
diagnostic 75gm 2 hour OGTT (diagnosed as GDM, if any one of the three 
values is exceeded) 
 FBS≥ 92mg/dl 
 Post 1 hour ≥ 180mg/dl 
 Post 2 hour ≥153 mg/dl       
 
 These cut offs are lower than the traditional values. The results are 
based on the HAPO study (hyperglycemia and pregnancy outcome study) 
which suggested increased complications occur even below the traditional 
cut offs used for diagnosis of GDM. 
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Following algorithm was suggested combining the recommendations  of 
ADA and IADPSG in 2011 
 
 Testing of all women at the first antenatal visit  <  13 weeks( early 
detection reduces complications 
 Test women who have any of the following risk factor Non-
Caucasian 
 BMI>25 
 History of GDM or prediabetes, 
 Unexplained still birth, 
 Malformed infant 
 Previous baby 4000gm or more 
 First-degree relative with diabetes mellitus 
 Glycosuria 
 Drug intake that raise glucose (steroids, betamimetics, 
atypicalAntipsychotics) 
 Polycystic ovarian syndrome, 
 Cardiovasculardisease, hypertension, hyperlipidemia. 
 
Criteria for diagnosis of overt diabetes include any one of the following: 
 FPG≥126mg/dl 
 RPG≥200mg/dl 
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 HBA1c ≥ 6.5% 
 
Criteria for diagnosis of GDM: 
 HBA1C<5.7 to 6.4 % 
 FPG≥ 92 to < 126  
 
Seshiah et al has debated ADA&IADPSE suggestion has certain 
disadvantage: 
 The Hapo study was essentially conducted in the Caucasian 
population except Bangkok and Hongkong. 
 
 For antenatal visit, mostly they not in fasting, the dropout rate is very 
high when is asked to come for an OGTT especially in developing countries 
where the number of antenatal visit are less. 
 
 Glycosylated Hb is not possible in low resource settings because of 
its cost and lack of technically qualified staff. 
 
 To overcome these problems in developing countries, the diabetics in 
pregnancy study group India (DIPSI) recommended a single step diagnostic 
procedure for all patients. The pregnant women are given 75 gm glucose 
orally irrespective of her fasting status or timing of previous meal. Post 2 
hour blood glucose value is taken, if it is more than or equal to 140 mg/dl 
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diagnosed as GDM. It is approved by ministry of health, Government of 
India and WHO.  
 
Advantages of DIPSI by Seshiah et al: 
 No need of fasting, it can be performed at the first visit itself. 
 It is both screening as well as diagnostic procedure. 
 It can be repeated again in 2nd and 3rd trimester. 
 
2006 WHO diabetes Criteria: 
Condition 2 hour glucose Fasting glucose 
 >140 (mg/dl) 126 (mg/dl) 
Normal <7.8 (<140) <6.1(<110) 
Impaired fasting 
glycaemia <7.8 (<140) ≥6.1(≥110)&<7.0(<126) 
Impaired glucose 
tolerance ≥7.8(≥140) <7.0(<126) 
Diabetes mellitus ≥11.1(≥200) ≥7.0(≥126) 
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ORAL GLUCOSE TOLERANCE TEST: 
 It’s done in the morning,, it needs at least overnight fasting of eight to 
fourteen hours.  three days before the test, the subject can take unrestricted 
diet, which contains at least   150g carbohydrate per day, no limitation of 
physical activity. Always seated during the test and should not smoke 
throughout the test.  
 
 The test done with oral glucose (100 gm anhydrous glucose powder) 
taken once. Then blood is drawn at hourly interval: 
 
BLOOD GLUCOSE Carpenter&Coustan NDDG 
FBS >95 mg/dl > 105mg/dl 
Post 1 hour >180mg/dl >190mg/dl 
Post 2 hour >155 mg/dl >165mg/dl 
Post 3 hour >140 mg/dl >145mg/dl 
 
NDDG (national diabetes data group) 
 
 Diagnostic criteria from NDDG have been used most often,Compared 
with the NDDG criteria, the carpenter and coustan criteria lead to an over 
diagnosis of GDM in pregnant women (54%), with an increased cost and no 
improvement in perinatal outcomes. 
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The American Diabetes Association cut off values to diagnose GDM (With 
100 g of glucose): 
 Fasting blood glucose level ≥95 mg/dl (5.33 mmol/L) 
 1 hr blood glucose level ≥ 180 mg/dl (10 mmol/L) 
 2 hr blood glucose level ≥ 155 mg/dl (8.6 mmol/L) 
 3 hr blood glucose level ≥ 140 mg/dl (7.8 mmol/L) 
 
 Another test using 75 g glucose load and measures the blood glucose 
levels in fasting and post 1 and 2 hours, use as the same reference values in 
ADA. This test will identifies only a few women, and is weak concordance 
(agreement rate)  with the 3 hour 100g test.  
 
 O’Sullivan and Mahan conducted a retrospective cohort study; they 
used 100 grams of glucose for oral glucose tolerance test. This was designed 
to  diagnose the risk of developing type two diabetes mellitus in the future. 
 
 In 1964, O’Sullivan and Mahan first demonstrated that the blood 
glucose values can be used to diagnose GDM. Four whole blood samples 
were drawn. The positive result requires   two values reaching or exceeding 
the cut off value.  
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 Based on further studies alterations in O’Sullivan’s criteria were 
made. Like whole blood changed to plasma sample, changes in cut off for 
GDM. 
 
URINARY GLUCOSE TESTING; 
 During pregnancy there is physiological glycosuria this is due to 
increased GFR. This is responsible for 50 % of women having glycosuria in 
their urine on dipstick tests at some time in their pregnancy. 
 
 When glycosuria is used as a marker of GDM it has   the sensitivity 
of 10 % and the positive predictive value of 20 % in first and second 
trimester. 
 
 Glycosuria of 2+ or above on 1 occasion or 1+ or above on 2 occasion 
or more detected by urine strip during routine antenatal visit may indicate 
undiagnosed GDM.  If this is observed may consider further testing to 
exclude GDM (NICE 2015) 
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MANAGEMENT  
 Treatment aim is to decrease the risk of both the mother and fetus.  
Adequate control of blood glucose is necessary to prevent fetal and maternal 
morbidity and thereby improves quality of life of mother and fetus. 
Crowther Et al (ACHOIS study 2005).  
 
 Follow up of GDM women is necessary, since most of them land up 
in type 2 DM. two to four months after delivery to do repeat OGTT.  These 
women are more prone for type two diabetes. Hence Regular follow up is 
needed. Low dose hormonal contraceptive pills can be advised 
 
 Insulin therapy is initiated if lifestyle modification and oral 
hypoglycemic drugs Fails. 
 
 Ultrasound detect macrosomia in pregnancy 
 
 GDM Women who was on insulin, with previous stillbirth, or with  
PIH are managed as overt diabetes.  
 
 Daily self monitoring of blood glucose is essential for women with 
GDM.  
 
 By proper monitoring of blood glucose we can prevent increase in 
perinatal mortality. 
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 4th international workshop, Conference on GDM, recommends 
maintaining the following capillary. Blood glucose values: preprandial 
glucose less than 95 mg/dl, 1hr PPBS<140 mg/dl, and 2hr PPBS < 120 
mg/dl.  
 
 ACOG Guidelines are the same except that the 1-hour postprandial 
glucose value is considered acceptable at either 130 or 140 mg/dl.  
 
 FBS< 90 mg/dl, PPBS< 120 mg/dl another strict guideline suggested 
by jovanovic Et al. 
 
 Agarwal Et al, 2007 conducted a prospective study recruited 668 
patients. This includes 334 women with GDM and 334 women without 
GDM, they calculated a mean blood glucose level; women with GDM who 
had a mean blood glucose level of 87 had  increased rate  of  IUGR and 104 
mg/dl had increased rate of  LGA infants comparable to the control group. 
Based on their study we conclude that hyperglycemia must be controlled, 
not to over treat, because it’s harmful to the fetus. It increases the risk of 
IUGR. 
 
 Maintenance of postprandial blood glucose is important as it is more 
associated with macrosomia than fasting blood glucose 
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 Occurding to Diabetes in Early Pregnancy Study conducted by Boyd 
Et al, the best predictor of percentile birth weight is postprandial glucose 
levels measured in third trimester of pregnancy.  Dose of insulin therapy is 
titrated according to PPBS, rather than preprandial glucose levels.  so the 
incidence of neonatal hypoglycemia, macrosomia, and cesarean delivery for 
cephalopelvic disproportion found to be decreased. 
 
Medical Nutrition Therapy 
 MNT aims to improve nutritional status of the mother and fetus, it 
also helps us to maintain adequate weight gain in the antenatal women, it 
also maintains normoglycemia and to prevent ketoacidosis. 
 
 First trimester of pregnancy does not need increased energy 
requirement normally.  Whereas in second and third   trimester an additional 
300kilocalories /day is required. 
 
 For women of normal weight with gestational diabetes calorie intake 
of 30 kcal/kg/day is recommended. 
 
 For obese women (BMI>30 kg/m2), a 33 % calorie restriction of their 
estimated energy needs is recommended (~25 kcal/kg/day).this much diet 
restriction does not cause any ketonuria. We need more calorie restriction in 
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morbidly obese women. Very cautious about ketosis when you advise more 
calorie restriction. 
 
 GDM mother who develops ketonemia during pregnancy is found to 
have long term complications in the children such as poor psychomotor 
skills and low intelligence. 
 
 It is ideal to measure pre-breakfast levels of ketone in patients, who 
practice to take low calorie diet or carbohydrate restricted diet.  
 
 Carbohydrates should be splitted throughout the day. GDM Women is 
advice to take three small- to medium-sized meals and three snacks per day. 
Such that to limit the carbohydrate intake to 40% of total daily calorie 
requirement which shows to decrease postprandial glucose. 
 
 Insulin resistance is high in the morning. So restricting the 
carbohydrate at breakfast to 33% is needed to meet the desired postprandial 
glucose.  
 
 Restricting carbohydrate to less than 42%,will decreases the large for 
gestational age infant in GDM mother, this lead on to  decrease in cesarean 
deliveries for CPD and macrosomia and also patient need decreased insulin 
therapy. 
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 Always advice low glycemic index diet, it will lower the PPBS, 
especially in late gestation. 
 
EXERCISE 
 The role of exercise in women with GDM has been proven to 
improve glycemic control LIZETT ET AI, Concluded from their study 
Previously women were discouraged from physical activity, because it leads 
to preterm delivery before 37 weeks.  Excercise is known to increase 
circulating level of both norepinephrine and epinephrine. Norepinephrine 
increases both strength and duration of uterine contraction but epinephrine 
inhibits uterine activity. This Meta analytical study concludes exercise 
improves glycemic control not harm the baby. 
 
 (NICE 2015) also recommends 30 minutes of mild to moderate 
exercise daily 
 
 Mottola MF conducted a randomized trial, it was a small trial they 
take two groups of people, one group were GDM women managed with   
diet and exercise, another group was managed with diet alone for 6 weeks.  
 
 They found that diet-and- exercise group had a significant decrease in 
HBa1c levels in both fasting and post 1-hour glucose level during OGCT 
compared to the diet group. 
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 American diabetes association recommends moderate exercise in 
women with GDM 
 
INSULIN 
 Insulin therapy is gold standard in the management of GDM and 
pregestational diabetes. Most association recommends  short acting regular 
insulin(onset of action 30 minutes lasting for 6-8 hours) and intermediate 
acting NPH insulin(ONSET OF ACTION 1-HOUR,lasting for 10-14hours). 
 
 Insulin therapy is initiated when MNT fails to maintain blood glucose 
level at desired ranges or when there is evidence of excessive fetal growth. 
 
Kick Et al concluded from their study 
 GDM women treated with insulin showed a decreased incidence of 
macrosomia and related morbidities it includes operative delivery and birth 
trauma. 
 
 A large prospective study conducted in almost 2500 women with 
GDM compared the effect of intensive versus conventional management of 
GDM.  Women were randomized to the intensive management group and 
conventional management group. Concluded from this study intensive 
management group showed decreased rate of macrosomia, cesarean section, 
shoulder dystocia, neonatal intensive care admission, respritory 
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complication. In this study GDM is diagnosed based on only one or more 
abnormal values rather than the current standards 
 
 No study to demonstrate optimal insulin regimen till date, the type 
and dose of insulin must be tailored to meet each patient’s requirements. 
Human insulin is currently recommended by ADA. Recent research has 
added newer rapid acting insulin lispro and aspart whose action begins 
within 15 minutes.  
 
 Insulin lispro is considered to be pregnancy cat B by FDA, it s 
appears to be safe in pregnancy, if we start after first trimester. ADA 
recommends human insulin until further studies. 
 
 Insulin aspart is considered as pregnancy category C by the FDA. 
Insulin aspart was effective in decreasing postprandial glucose 
concentration. More studies will require for ensuring the safety of the drug.  
 
 Only case report is available regarding Use of insulin glaring in 
pregnancy. We need more number of clinical trials to evaluate use of 
glargine in pregnancy. It is pregnancy category C by FDA.  
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ORAL HYPOGLYCEMIC AGENTS (OHA): 
 Two OHA have been used in pregnancy Metformin (Biguanide group 
and gluburide). ADA also recommends, in the past, there was concern 
regarding the teratogenecity of these drugs due to their transplacental 
transfer. Metformin can be used in pregnant women with GDM. It’s 
considered to be pregnancy category B by FDA 
 
 Jamie et al, they found out Metformin is an effective alternative to 
insulin in patient with GDM. There is no significant difference in birth 
weigh between the Metformin and insulin group. 
 
 Another study it’s a retrospective cohort study found women treated 
with Metformin had an increased prevalence of preeclampsia and perinatal 
mortality, although larger studies are needed for evaluating the safety of the 
Metformin during pregnancy.  
 
 Pratap et al conducted prospective study involving women with 
PCOS or women with type-two DM who used Metformin in pregnancy; 
they found no unpleasant pregnancy outcome.  
 
 First generation sulfonylurea’s chlorpropamie and tolbutamide could 
cross the placenta, stimulate the fetal pancreas, cause fetal 
hyperinsulinemia.  
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 Transfer of second generation sulfonylurea’s   glyburide  can  cross 
the human placenta  insignificantly  in experimental model. 
 
 ADA( 2016),ACOG not recommended this drug ,we need larger 
studies to support this drug  
 
Uric acid and gestational diabetes mellitus                 
 Because of risk factor GDM prevalence is increasing, Hedderson and 
Ferrara  
 
 Another study conducted by Kim Et al, those women with gestational 
diabetes are more prone for developing preeclampsia, because of this reason 
they prone for induction of labour and its lead  to increased cesarean rate,  
GDM is risk factor for development of type 2 DM in feature. 
 
 Hollander Et al 2007, preeclampsia is a complication of GDM but 
association between the two is not understood well. But several studies 
support underlying common Pathophysiology. It includes insulin resistance, 
chronic inflammation and endothelial dysfunction. Some common risk 
factor also found between the two conditions, such as increased BMI and 
advanced age. 
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 Poly cystic ovary syndrome was the main reason for development of 
gestational diabetes mellitus according to toulis et al, 2009.  
 
 Essential hypertension was the main reason for development of 
gestational diabetes mellitus according to tamas et al, 2001.  
 
 Monozygotic twins 70% and dizygotic twins 20-30% were reasons 
for development of gestational diabetes mellitus according to kaprio et al, 
1992; lebtovirta et al,  
 
 Enzyme xanthine oxidase/dehydrogenase is needed for uric acid 
synthesis,Uric acid is produced from purine metabolism( catabolism) 
(Roberts et al) 
 
 Dehghan et al 2008 concluded from their study  
 
 In non pregnant women, uric acid is linked with insulin resistance and 
is an independent risk factor for development of type 2 diabetes within 10 
years 
 
 Simmikharb 2007concluded from his study decreased 
detoxification or free radical scavenging capacity in GDM and 
Compensatory elevation of uric acid confers protection in pregnancies 
complicated by diabetes 
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 Aparna et al 2014, concluded from their study raised serum uric acid 
levels in early pregnancy as a risk factor for subsequent development of 
GDM in an Indian population. Diagnostic criterion 3.4 mg/dL appears to 
have good sensitivity and specificity in identifying those patients who are 
most likely to develop GDM later in pregnancy. This, if replicated and 
confirmed, can have important therapeutic implications in helping identify 
and manage GDM early, and thus prevent adverse maternal and fetal 
complications. 
 
 Two proposed hypothesis by which uric acid can cause insulin 
resistance. 
 
 First hypothesis, uric acid causes endothelial dysfunction and 
Decrease nitric oxide production by endothelial cells.Insulin mediated 
Glucose uptake into the cell (adipose tissue and skeletal muscle)  depends 
on nitric oxide.Hence decrease in nitric oxide lead to decrease in glucose 
uptake and development of insulin resistance. (Cook et al, 2003) 
 
 Another mechanism by which uric acid causes insulin resistance may 
be That uric acid causes inflammation and oxidative stress in adipocytes  
Which contributes to metabolic syndrome in mice? (Sautin et al, 2007)Uric 
Acid:It is a diprotic acid, its pka1 and pka2 value was 5.4 and 10.3. It has 
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purine functional group, aromatic because of purine functional group, strong 
alkali at high pH. 
 
URIC ACID 
Biology: 
 Xanthine and hypoxanthine forms uric acid by enzyme called   
xanthine oxidase, Xanthine and hypoxanthine produced from purine, kidney 
excretes uric acid. It is mostly released in hypoxic condition. In mammal’s 
uric acid oxidized to allantoin by enzyme uricase.   Ascorbic acid and uric 
acid act as both reducing agent and antioxidants. Majority of antioxidant 
capacity of blood mainly mediated by uric acid, kidney excrete uric acid 
about 70% daily. 
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Uric acid formation; 
       ADENINE 
 Phosphate+  Phospho-ribosyl pyrophosphate synthetase 
ADENINE MONO PHOSPHATE 
                    Sugar+                 nucleotidase 
  ADENOSINE  
          Ammonia               adenosine deaminase 
 
  INOSINE GUANOSINE 
Sugar phosphate            nucleoside phosphorylase                   sugar 
phosphate 
                  HYPOXANTHINE                             GUANINE 
                                           Xanthine oxidase                                 guanase 
                        XANTHINE 
                                                Xanthine oxidase 
 
                       URIC ACID 
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 High level of uric acid is called as hyperuricemia,impaired renal 
excretion also leads to hyperuricemia.It causes  gout, Lesch-nychan 
syndrome, cardiovascular disease, uric acid stone formation and metabolic 
syndrome. 
 
 Nagakawa et al concluded from their study that fructose induced 
hyperuricemia associated with metabolic syndrome. Mainly due to increased 
consumption of fructose-containing beverages this may associated with 
obesity and diabetes. 
 
Causes of low uric acid 
 Also known as hypouricemia, causes of hypouricemia are low intake 
of zinc, more commonly associated with oral contraceptive all contributes to 
low uric acid level 
 
 Xanthine oxides are a Fe-Mo enzyme, so deficiency of iron and 
molybdenum also leads to hypouricemia. 
 
 In chronic renal failure patient, a drug used for prevention of 
hyperphosphataemia is sevelamer, will reduce serum uric acid.Low uric acid 
leads to Multiple sclerosis and Oxidative stress. 
  
Materials and Methods 
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MATERIALS AND METHODS 
 
 Prospective study conducted in the Institute of Obstetrics and 
GynaecologyEgmore,chennai 
 
 Aim of work will be explained to the pregnant women and informed 
consent obtained 
 
 Study population; 200 antenatal women, the study conducted for eight 
months from January 2016 to august 2016 
 
INCLUSION CRITERIA 
 Antenatal women in their 1st trimester of pregnancy (<13 weeks of 
Gestation). 
 
EXCLUSION CRITERIA 
 Renal disease 
 Liver disease 
 Pre gestational diabetes 
 Chronic hypertension 
 Gout 
 Smoking and alcohol intake 
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 Drugs known to increase Uric acid levels in blood. Eg aspirin, 
phenothiazines, diuretics. 
 
METHODS 
 Maternal plasma uric acid  measured before 13 weeks venous 
sample. 
Blood sample will be Centrifuged  to separate the serum  stored 
at – 70 degree up to examination. 
 
 It is measured using a Colorimetric assay (kit U7581-120; Pointe 
scientific INS, Canton, MI) with a detection limit of 10 mg/dl. 
 
 Cut off taken in my study is 3.6 mg/dl (AJOG,Vol 201,Oct 2009) 
 
SCREENING FOR GDM 
 All patients will undergo  random oral GCT (75gms) between 22-
24 weeks. 
 
 If the value is > 200 mg/dl  patient is considered to have GDM 
                                                OR 
 If plasma glucose level > 140 mg/dl  patient at increased risk of 
developing GDM  will then undergo 3 hr oral GTT 
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 FBS level  oral intake of 100 gms glucose  measuring blood 
glucose level at 1,2 and 3 hrs. 
 
 Patients are considered to have GDM if 2 or more values of the 4 
exceed described in carpenter &Coustan Criteria (American diabetes 
association 2009 ) 
 
  
Analysis of Results 
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ANALYSIS OF RESULTS 
 
 
ASSOCIATION BETWEEN AGE GROUP  AND GDM 
 
 
Crosstab 
   OUTCOME  
   NO  GDM GDM Total 
AGE 
GROUP 
UPTO  20 
YEARS 
Count 4 5 9 
% within 
OUTCOME 4.2% 4.8% 4.5% 
21 - 25 YEARS 
Count 57 60 117 
% within 
OUTCOME 59.4% 57.7% 58.5% 
26 - 30 YEARS 
Count 27 28 55 
% within 
OUTCOME 28.1% 26.9% 27.5% 
31-35 YEARS 
Count 6 6 12 
% within 
OUTCOME 6.3% 5.8% 6.0% 
36 YEARS & 
ABOVE 
Count 2 5 7 
% within 
OUTCOME 2.1% 4.8% 3.5% 
 Total 
Count 96 104 200 
% within 
OUTCOME 100.0% 100.0% 100.0% 
 
Chi square=1.174   P=0.882   Not significant. 
 There is no statistical significance between GDM and Non GDM patients with 
respect to age. 
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Chi-Square Tests 
 Value Df Asymp. Sig.  (2-sided) 
Pearson Chi-Square 1.174a 4 .882 
Likelihood Ratio 1.215 4 .876 
Linear-by-Linear Association .214 1 .643 
N of Valid Cases 200   
a. 4 cells (40.0%) have expected count less than 5. The minimum expected count 
is 3.36. 
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ASSOCIATION BETWEEN PARITY AND GESTATIONAL DIABETES 
MELLITUS 
  
   OUTCOME  
  Crosstab NO  GDM GDM Total 
OBS CODE 
multi 
Count 51 51 102 
% within 
OUTCOME 53.1% 49.0% 51.0% 
primi 
Count 45 53 98 
% within 
OUTCOME 46.9% 51.0% 49.0% 
 Total 
Count 96 104 200 
% within 
OUTCOME 100.0% 100.0% 100.0% 
 
 
Chi square=0.334   P=0.564    Not significant. 
 There is no statistical significance between GDM and Non GDM patients with 
respect to parity. 
36 
 
 
 
 
This bar diagram shows relation between the parity and GDM, there wsa no 
difference between the parity and GDM.  
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ASSOCIATION BETWEEN PIH AND GESTATIONAL DIABETES 
MELLITUS  
 
  
Crosstab 
OUTCOME 
Total 
NO  GDM GDM 
Count 83 74 157 
% within OUTCOME 86.5% 71.2% 78.5% 
Count 13 30 43 
% within OUTCOME 13.5% 28.8% 21.5% 
Count 96 104 200 
% within OUTCOME 100.0% 100.0% 100.0% 
 
Chi square=6.928  P=0.008     significant. 
 
 There is a statistical significance between GDM and Non GDM patients with 
respect to PIH. 
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Chi-Square Tests 
 Value Df 
Asymp. 
Sig.  
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 6.928a 1 .008   
Continuity 
Correctionb 6.051 1 .014   
Likelihood Ratio 7.104 1 .008   
Fisher's Exact Test    .010 .007 
Linear-by-Linear 
Association 6.893 1 .009   
N of Valid Cases 200     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 
20.64. 
b. Computed only for a 2x2 table 
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This bar chart shows association between GDM and PIH 
More number of GDM women developed PIH,this shows some common 
association between GDM and pregnancy induced hypertension 
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ASSOCIATION BETWEEN FAMILY HISTORY AND GESTATIONAL 
DIABETES MELLITUS  
 
 
 
OUTCOME  
NO  
GDM GDM Total 
FAMILY 
HISTORY 
NO 
Count 95 96 191 
% within FAMILY 
HISTORY 49.7% 50.3% 100.0% 
% within OUTCOME 99.0% 92.3% 95.5% 
% of Total 47.5% 48.0% 95.5% 
YES 
Count 1 8 9 
% within FAMILY 
HISTORY 11.1% 88.9% 100.0% 
% within OUTCOME 1.0% 7.7% 4.5% 
% of Total .5% 4.0% 4.5% 
 Total 
Count 96 104 200 
% within FAMILY 
HISTORY 48.0% 52.0% 100.0% 
% within OUTCOME 100.0% 100.0% 100.0% 
% of Total 48.0% 52.0% 100.0% 
 
Chi square=5.138  P=0.023     significant. 
 There is statistical significance between GDM and Non GDM patients with 
respect to family history 
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Chi-Square Tests 
 Value Df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 5.138a 1 .023   
Continuity 
Correctionb 3.707 1 .054   
Likelihood Ratio 5.883 1 .015   
Fisher's Exact Test    .036 .023 
Linear-by-Linear 
Association 5.112 1 .024   
N of Valid Cases 200     
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count 
is 4.32. 
b. Computed only for a 2x2 table 
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ASSOCIATION BETWEEN  PREVIOUS HISTORY OF GDM 
AND GESTATIONAL DIABETES MELLITUS 
 
   OUTCOME  
   NO  GDM GDM Total 
PRE HISTORY 
OF GDM 
NO 
Count 96 101 197 
% within 
OUTCOME 100.0% 97.1% 98.5% 
YES 
Count 0 3 3 
% within 
OUTCOME .0% 2.9% 1.5% 
 Total Count 96 104 200 
 
 
Chi square=2.811  P=0.094 not  significant. 
 There is no statistical significance between GDM and Non GDM patients 
with respect to previous h/o GDM 
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Chi-Square Tests 
 Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 2.811a 1 .094   
Continuity 
Correctionb 1.198 1 .274   
Likelihood Ratio 3.966 1 .046   
Fisher's Exact Test    .247 .139 
Linear-by-Linear 
Association 2.797 1 .094   
N of Valid Cases 200     
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count 
is 1.44. 
b. Computed only for a 2x2 table 
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ASSOCIATION BETWEEN  OTHER RISK FACTORS AND 
GESTATIONAL DIABETES MELLITUS 
 
 
Crosstab 
   OUTCOME  
   NO  GDM GDM Total 
OTHER RISK 
FACTORS 
NO 
Count 95 99 194 
% within 
OUTCOME 99.0% 95.2% 97.0% 
YES 
Count 1 5 6 
% within 
OUTCOME 1.0% 4.8% 3.0% 
 Total Count 96 104 200 
 
Chi square=2.433  P=0.119  not significant. 
 
 There is no  statistical significance between  GDM  and  Non GDM  
patients  with  respect to other risk factor such as previous big baby, multiple 
pregnancy 
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Chi-Square Tests 
 Value Df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact 
Sig. 
(1-
sided) 
Pearson Chi-Square 2.433a 1 .119   
Continuity Correctionb 1.311 1 .252   
Likelihood Ratio 2.673 1 .102   
Fisher's Exact Test    .214 .126 
Linear-by-Linear 
Association 2.421 1 .120   
N of Valid Cases 200     
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count 
is 2.88. 
b. Computed only for a 2x2 table 
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RELATION BETWEEN BMI AND GDM 
 
 
Group Statistics   
 OUTCOME N Mean Std. Deviation 
Std. 
Error 
Mean 
t P 
BMI 
GDM 104 23.097 1.8614 .1825 2.687 0.008 
NO  GDM 96 22.434 1.6039 .1637   
 
 There exists a statistical significance (p value 0.008) between GDM & Non 
GDM patients with respect to BMI mean level. The Mean BMI for GDM patients 
were 23.097, whereas Mean BMI for Non GDM patients were 22.434 
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Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for Equality 
of Means 
  F Sig. T Df 
BMI 
Equal variances 
assumed .000 .984 2.687 198 
Equal variances not 
assumed   2.703 197.087 
 
 
 
Independent Samples Test 
  t-test for Equality of Means 
  Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
BMI 
Equal variances assumed .008 .6627 .2466 
Equal variances not 
assumed .007 .6627 .2452 
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Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
BMI 
Equal variances assumed .1764 1.1491 
Equal variances not assumed .1792 1.1463 
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RELATION BETWEEN GDM AND AGE 
 
 
 
 There was a no statistical significance (p value 0.459) between GDM & 
Non GDM patients with respect to   age level. The    Mean age for GDM patients 
were 25.46, whereas Mean age for Non GDM patients were 25.05 
 
 
Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for Equality of 
Means 
  F Sig. T Df 
AGE 
Equal variances 
assumed .154 .695 .741 198 
Equal variances not 
assumed   .743 197.987 
 
  
Group Statistics   
 OUTCOME N Mean Std. Deviation 
Std. 
Error 
Mean 
t P 
AGE 
GDM 104 25.46 4.036 .396 0.741 0.459 
NO  GDM 96 25.05 3.754 .383   
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Independent Samples Test 
  t-test for Equality of Means 
  Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
AGE 
Equal variances assumed .459 .409 .552 
Equal variances not 
assumed .458 .409 .551 
 
 
 
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
AGE 
Equal variances assumed -.680 1.499 
Equal variances not assumed -.677 1.496 
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RELATION BETWEEN SERUM URIC ACID AND GESTATIONAL 
DIABETES MELLITUS 
 
Group Statistics   
 OUTCOME N Mean Std. Deviation 
Std. 
Error 
Mean 
T P 
serum 
uric acid 
GDM 104 4.275 1.0753 .1054   
NO  GDM 96 3.250 .6142 .0627 8.187 0.0001 
 
 There exists a statistical   significance (p value 0.0001) between GDM & 
Non GDM patients with respect to   serum uric acid level. The  biomarker of  
Mean serum uric acid  for  GDM  patients were  4.275, whereas Mean age  for 
Non  GDM  patients were  3.250 
 
Independent Samples Test 
  Levene's Test for Equality of Variances 
t-test for Equality 
of Means 
  F Sig. T Df 
serum uric 
acid 
Equal variances 
assumed 17.993 .000 8.187 198 
Equal variances not 
assumed   8.356 166.173 
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Independent Samples Test 
  t-test for Equality of Means 
  Sig. (2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
serum uric 
acid 
Equal variances 
assumed .0001 1.0250 .1252 
Equal variances not 
assumed .000 1.0250 .1227 
 
 
 
Independent Samples Test 
  t-test for Equality of Means 
  95% Confidence Interval of the Difference 
  Lower Upper 
serum uric acid 
Equal variances assumed .7781 1.2719 
Equal variances not 
assumed .7828 1.2672 
 
This shows stastisticaly significant association between  serum uric acid 
and GDM. 
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 The Receiver Operator Curve drawn showed serum uric acid as a predictor 
of GDM with Area under Curve of 0.81 with a sensitivity of 87.5%, specificity of 
79.2% at an Optimum criterion of >3.6mg/dl 
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ROC curve 
 
Variable Serum Uric acid 
Classification variable GDM 
  
 
Sample size  200 
Positive group : GDM = 1 104 
Negative group : GDM = 0 96 
  
 
Disease prevalence (%) Unknown 
  
 
Area under the ROC curve (AUC)  
 Area under the ROC curve (AUC)  0.819912 
Standard Errora 0.0310 
95% Confidence intervalb 0.759522 to 0.870554 
z statistic 10.329 
Significance level P (Area=0.5) <0.0001 
 
a Hanley & McNeil, 1982 
b Binomial exact 
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 Scatter Diagram 
 
 
 
 This diagram shows linear relationship between serum uric acid and 
gestational diabetes. 
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Regression 
 
Dependent Y OGCT 
Independent X Serum Uric acid 
  
 
Sample size 200 
Coefficient of determination R2 0.3086 
Residual standard deviation 16.7075 
  
 
Regression Equation 
  
y = 97.7561  +  10.9077  x 
Parameter Coefficient Std. Error 95% CI t P 
Intercept 97.7561 4.5452 88.7929 to 106.7193 21.5076 <0.0001 
Slope 10.9077 1.1602 8.6198 to 13.1956 9.4017 <0.0001 
  
From this equation we can calculate OGCT value, y is OGCT, x is serum uric 
acid  
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Analysis of Variance 
  
Source DF Sum of Squares Mean Square 
Regression 1 24674.0156 24674.0156 
Residual 198 55269.9044 279.1409 
  
 
 
 
F-ratio 88.3927 
Significance level P<0.0001 
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Binary Logistic Regression 
Coefficients and Standard Errors 
  
Variable Coefficient Std. Error P 
BMI 0.31839 0.10752 0.0031 
Serum_Uric_acid 1.77979 0.29829 <0.0001 
FAMILY_HISTORY 2.55302 1.16402 0.0283 
Constant -13.8106   
  
 
 BMI, familyhistory, serum uric acid all significant parameter individually 
with bivariat analysis were Included in binary logistic regression analysis. The 
dependant variable is GDM/noGDM. The following table Shows all the three 
parameters included in the final model. The log it equation showsLogit= -13.8106 
+ 0.31839(BMI) + 1.77979 (serum uric acid) +2.55302(Family History) 
Odds Ratios and 95% Confidence Intervals  
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The following table shows all the three parameters included in the final model 
Variable Odds ratio 95% CI 
BMI 1.3749 1.1137 to 1.6974 
Serum_Uric_acid 5.9286 3.3040 to 10.6379 
FAMILY_HISTORY 12.8458 1.3120 to 125.7759 
  
 
 The odds ratio of BMI was 1.3749, serum uric acid was 5.928 and family 
history was 12.845. This shows one fold increase in BMI was associated with 1.3 
times increased risk of developing GDM, elevated serum uric acid was associated 
with nearly six times the risk of developing GDM 
 
 
Hosmer & Lemeshow test 
  
Chi-square 12.3650 
DF 8 
Significance level P = 0.1356 
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Classification table (cut-off value p=0.5) 
  
Actual group Predicted group Percent correct 
 0 1  
Y = 0 76 20 79.17 % 
Y = 1 22 82 78.85 % 
Percent of cases correctly classified 79.00 % 
  
 
 
ROC curve analysis 
  
Area under the ROC curve (AUC) 0.847 
Standard Error 0.0276 
95% Confidence interval 0.790 to 0.894 
 
 
 
 ROC curve of log it shows AUC of 0.84 (combination of BMI, 
FAMILY HISTORY, serum uric acid) which is greater than the AUC of 
serum uric acid alone.serum uric acid AUC is 0.81 mg/dl, This clearly 
indicates serum uric acid is a very good predictor with sensitivity of 87.5%, 
specificity of 79.5%, criterion > 3.6mg/dl  
 
  
Discussion 
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DISCUSSION 
 
 In this study conducted in Institute of Obstetrics and Gynaecology, 
Egmore, Chennai, total of 200 patients have been analyzed and their 
relationship with uric acid and gestational diabetes mellitus and risk factors 
have been studied. Similar studies also done by AJOG, October 2009 did 
the study of total of 1570 patients. 
 
 Assuit Et al analyzed 812 patients  
 Helmymotawe et al analyzed 1200 patients 
 Moden et al analyzed 1016 patients 
 Aparna et al analyzed 225 patients 
 
 The Receiver Operator Curve drawn showed serum uric acid as a 
predictor of GDM with Area under Curve of 0.819[95% CI: (0.759-0.870)] 
with a sensitivity of 87.5%, specificity of 79.2% at an Optimum criterion 
>3.6 mg/dl 
 
 First trimester uric acid concentrations > 3.6 mg/dl were associated 
with a trend towards increased risk of developing gestational diabetes 
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(adjusted ODDS RATIO =5. 95%CI: 0.759-.870) compared to women with 
concentrations below this level. 
 
 ROC curve of log it shows AUC of 0.84 (combination of BMI, 
FAMILY HISTORY, serum uric acid) which is greater than the AUC of 
serum uric acid alone.serum uric acid AUC is 0.81 mg/dl, This clearly 
indicates serum uric acid is a very good predictor with sensitivity of 87.5%, 
specificity of 79.5%, criterion > 3.6mg/dl  
 
PARITY- 
  Primigravida were 49% (98 patients) 
 Multigravida were 51% (102 patients)                                                                                                                
 
URICACID- 
 Cut off taken in my study was 3.6mg/dl (AJOG, VOL 201 issue 4, 
Oct 2009) 
 
Out of total 200 patients: 
 Uric acid < =3.6 mg/dl in 99 patients 
 Uric acid >3.6 mg/dl in 111 patients 
 As suit et al had 133 patients with raised uric acid concentration 
 Helmy et al had 312 patients with raised uric acid concentration 
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SPOT TEST 
Spot test was done at 22-24 weeks (AJOG 2009) 
 <140mg/dl was noticed in 96 patients (48%) 
 >140-200 mg/dl noted in 104 patients (52%) 
 > 200mg/dl – nil 
 
URIC ACID CONCENTRATION AND DEVELOPMENT OF GDM 
Uric  acid No GDM GDM 
Normal 76 13 
Abnormal 20 91 
 
 Therefore it was noticed that out of the 99 patients with normal uric 
acid 13 patients developed GDM(13.1%) and out of the 111 patients with 
raised uric acid 91(81.5%) patient developed GDM 
 
RISK FACTORS 
Risk factors were present in 28patients (14%) 
No risk factors in 172patients (86%) 
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Patients with normal and abnormal uric acid were studied in relation to their 
risk factors and were found that 
 Patients Risk factor No risk 
Normal uric acid 99 14 85 
Abnormal UA 111 14 97 
 
RELATION OF NORMAL URIC ACID CONCENTRATION WITH 
RISK FACTOR AND DEVELOPMENT OF GDM  
Totaly 99 patients had normal uric acid  
NORMAL URIC 
ACID RISK FACTOR NO RISK FACTOR 
99 14 85 
GDM In this group 8 5 
 
Therefore patient with normal uric acid and with risk factors developing 
GDM were 8 patients (8.08%) 
  
65 
 
 
 
RELATION OF ABNORMAL URIC ACID CONCENTRATION 
WITH RISK FACTOR AND DEVELOPMENT OF GDM  
 
ABNORMAL URIC 
ACID RISK FACTOR NO RISK FACTOR 
111 14 97 
GDM in this group 14 77 
 
 Therefore patients with abnormal uric acid and with risk factors 
developing GDM were (12.61%) 
 
DEVELOPMENT OF RISK FACTOR AND GDM 
 RISK FACTOR NO RISK FACTOR 
TOTAL( 200)          28 172 
TOTAL GDM( 104) 22 82 
 
Therefore, 22(21.15%) patients developed GDM of the 28 patients with risk 
factors 
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RISK FACTOR STRATIFICATION IN THE TOTAL POPULATION 
STUDIED 
 
  GDM 
NO RISK FACTOR 172 82 
Both parents DM 3 1 
>35years 7 5 
Father DM 5 5 
MOTHER DM 4 3 
Pre preg GDM 3 3 
Others 6 5 
Total 200 104 
 
 Correlation between serum uric acid and pregnancy induced 
hypertension and GDM 
 
  PIH 
Normal uric acid 99 11 
Abnormal uric acid 111 32 
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 43 patient developed PIH out of 200 
 
 Therefore it was noticed that out of the 99 patients with normal uric 
acid  11 patients developed PIH(11.1%) and out of the 111 patients with 
raised uric acid 32 patient developed PIH(28.8%) 
 
RELATION OF URIC ACID CONCENTRATION WITH PIH AND 
DEVELOPMENT OF GDM  
 GDM NO GDM 
Normal UA+PIH(11) 1 10 
Abnormal UA+PIH(32) 29 3 
 
 OUT OF 11 PIH Patient with normal uric acid 1 patient developed 
GDM and out of 32 PIH patients with abnormal uric acid 29 patient 
developed GDM. This shows elevation of uric acid associated with 
metabolic syndrome. 
 
The main reason for development of GDM as per my study was: 
 History of diabetes mellitus in family member, increased BMI,In this 
study normal uric acid group developing GDM was 13.1% AND abnormal 
uric acid group developing GDM 81.5% was statistically significant p value 
0.0001, and also from this study normal uric acid group with risk factor 
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developing GDM was 8.08% and abnormal uric acid group with risk factor 
developing GDM was 12.61%, concluded from this observation serum uric 
acid act as a individual risk factor for the development of GDM 
 
 According to Hollander Et al, 2007- advanced maternal age and 
increased BMI  was the main reason for development of GDM   
 
 History of GDM in previous pregnancy association with GDM. 
studied by Toroloni Et al, 2009. 
 
 No risk factors in 50% of GDM concluded from cook Et al.  
 
 Early diagnosis of GDM or with patients who are at risk of 
developing GDM should be properly screened to prevent the maternal and 
fetal complication due to Gestational diabetes 
 
 In this study mean age of population was 25.4 without any statistical 
difference among women .so the incidence of GDM was low in this age 
group  
 
 In this study 200 pregnant women analyzed. Among these 49% are 
primi and 51% are multi. 
 
 There was no statistical difference between parity. This was 
correlated with study done by Dunlop Et al.  
69 
 
 
 
 But this was not correlated with study of nagalakshmi et al which 
shows increased incidence of GDM in primi. 
 
 In this study there was significant correlation between BMI and 
GDM. The p value was statistically significant-0.008. This was proved from 
various studies. Recent studies of laughon Et al showed that there is strong 
correlation between these two parameters. 
 
 Family history has significant correlation with GDM. This was 
proved from various studies. This was proved from Ratankar Et al study 
also. 
 
 In this study out of 200 cases 111 cases has increased level of serum 
uric acid more than 3.6mg/dl in the first trimester. Among them 91 patients 
developed GDM. There was statistical significance between serum uric acid 
and GDM 
 
 The p valve was very significant -0.0001 
 
 
 This was proved from various studies including langen et al ,Reece 
2010, AJOG 2009 showed significant similarities also. In this study odds 
ratio was 5.95. This shows one fold increase in serum uric acid associated 
with 5.9 fold increased risk of GDM 
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 According to Boyle et al analysis there is low level of serum uric acid 
level in first and second trimester and increased in third trimester normally 
occurs in a healthy women  
  
 But the cases that had increase in serum uric acid in first trimester is 
abnormal this leads to  increased  insulin resistance and metabolic syndrome 
and this leads to development of GDM and PIH 
 
 ROC curve of log it shows AUC of 0.84 (such as BMI, FAMILY 
HISTORY, serum uric acid) which is greater than the AUC of serum uric 
acid alone. This clearly indicates serum uric acid is a very good predictor 
with sensitivity of 87.5%, specificity of 79.5%, criterion> 3.6mg/dl with 
AUC 0.819 
 
 So in the screening itself if we take serum uric acid we can predict the 
GDM along with family history and BMI. So earlier detection will prevent 
both maternal and fetal complications 
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Limitations 
 
1) Study population was small, 
2) Influence of diet on serum uric acid was not studied, 
3) Other important variable association with uric acid also not studied 
(race, ethintyet) 
4) Fetal outcome also not studied 
  
Summary 
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SUMMARY 
 
 Diabetes is one of the common medical disorder in India, and it’s not 
so uncommon to encounter in the pregnant women. It is associated with 
high perinatal mortality and morbidity if it was not well controlled. Early 
diagnosis and preconception advice, optimum glycemic control, good 
monitoring of fetal well being are all essential to improve the perinatal 
outcome. 
 
 Since Indian women are more prone for developing type two DM, so 
universal screening is offered to Indian mothers to prevent maternal and 
fetal complications. 
 
 Early diagnosis by means of screening and history 
 
 To attain optimum glycemic control by means of diet, exercise and 
insulin, oral hypoglycemic agents, and also by daily self monitoring of 
blood glucose is essential, 
 
 During antenatal period fetal well being is assured by ultrasound and 
biophysical profile 
 During intrapartum period maintain blood glucose level below 140 
mg/dl is essential to avoid neonatal hypoglycemia. 
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  Progress of labor should be closely monitored with vigilant watch for 
shoulder dystocia 
 
 GDM mother is more prone   for type 2 diabetes in the future. 75 gm 
GTT should be done six to twelve week after delivery then once in three 
years.  
 
 According to this study done in institute of obstetrics and gynecology 
first trimester uric acid is connected with a significant risk of developing 
GDM and it was observed that risk factors  also involved  in the 
development of GDM.  This is supported by various studies like 
 
 AJOG, 2009 
 Reece, 2010 
 Assuit Et al analyzed 812 patients  
 Helmymotawe et al analyzed 1200 patients 
 Moden et al analyzed 1016 patients 
 Aparna et al analyzed 225 patients 
 
 Uric acid was increased with protein intake, alcohol consumption, 
decreased excretion or increased endogenous production 
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 Study done by Lind Et al.1984 it has been proved that uric acid was 
positively correlated with fasting serum glucose and insulin resistance as 
well as features of metabolic syndrome, including waist circumference, Low 
HDL, hypertriglyceridemia, hypertension and fasting glucose >110mg/dl 
(Cappuccino Et al, 1993) concluded from his study GDM women is more 
prone for type two diabetes mellitus in feature. 
 
 The Receiver Operator Curve drawn showed serum uric acid as a 
predictor of GDM with Area under Curve of 0.819[95% CI: (0.759-0.870)] 
with a sensitivity of 87.5%, specificity of 79.2% at an Optimum criterion 
>3.6mg/dl. 
 
 First trimester uric acid concentrations >3.6 mg/dl were associated 
with a tendency towards increased risk of developing gestational diabetes 
(adjusted ODDS RATIO =5. 95%CI: 0.759-.870) compared to women with 
concentrations below this level. 
 
 ROC curve of log it shows AUC of 0.84 (combination of 
BMI,FAMILY HISTORY, serum uric acid) which is greater than the AUC 
of serum uric acid alone .This clearly indicates serum uric acid is a very 
good predictor of GDM and the risk increases when there are other 
associated risk factors. 
  
Conclusion 
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CONCLUSION 
 
 Based on the results and the methodology employed, we conclude 
that there  is risk of development of GDM with elevated levels of serum uric 
acid in the first trimester. This relationship is independent of age, parity, 
BMI and family history of diabetes mellitus though there is association of 
these variables (advanced maternal age, high parity, increased BMI and 
positive family history) with GDM. Uric acid levels at <13 weeks of 
gestation is more significantly associated with risk of development of GDM 
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Annexures 
PROFORMA 
 
Serial No; 
Hospital No 
Name 
Age 
Address 
Phone No 
Booked&Unbooked 
Socio Economic Status 
Obstetric Score 
Gestational Age 
Present Obs H/O 
Menstrual H/O 
Marital H/O 
Obstetric H/O 
Past  H/O  : H/O GDM In First Pregnancy, Renal , Liver Disease,  
     Chronic Hypertension,Gout, Drug Intake                                                   
Family H/O  :  H/O DM In First Degree Relative 
Personal H/O  :  Diet, Smoking, Alcohol, Weight gain during pregnancy 
 
EXAMINATION 
 
Height 
Weight 
BMI 
Temperature 
Pulse Rate 
Blood Pressure 
Pallor 
Pedal Oedema 
 
SYSTEMIC EXAMINATION 
Cardiovascular System 
Respiratory System 
Central Nervous System 
Abdomen 
 
INVESTIGATION 
Haemoglobin 
Packed Cell Volume 
Serum Uric Acid 
Blood Group 
HIV 
HBSAG 
VDRL 
OGCT 
GTT 
USG 
  
ABBREVIATIONS 
 
ACOG - American college of obstetrics and gynaecology 
ADA  - American Diabetes Association 
BMI  - Body mass index 
DIPSI  - Diabetes in pregnancy study group india 
DM  - Diabetes Mellitus 
FBS  - Fasting Blood Sugar 
GDM  - Gestational Diabetes Mellitus 
GTT  - Glucose Tolerance Test 
HBA1c - Glycosylated Haemoglobin 
IADPSG - International Association of Diabetes and Pregnancy Study Group 
OGCT - Oral Glucose Challenge Test 
PIH  - Pregnancy Induced Hypertension 
PPBS  - Post Prandial Blood Sugar 
UA  - Uric Acid 
  
 
 
  
 
   
  
  
  
 
SI No Name Age Obs Code Risk Factors BMI Sr.Uric acid OGCT GTT FBS PPBS PIH treatment
1 saranya 22 multi - 19 2.6 96 - - - 0 -
2 judith 22 primi - 23.1 2.2 102 - - - 0 -
3 jegadeswari 20 primi - 19.8 3.6 102 - - - 0 -
4 bhavani 27 primi - 24 3.1 106 - - - 0 -
5 sudha 28 primi - 23.8 2.6 108 - - - 0 -
6 kanmani 34 multi both parents DM 22 3.8 108 - - - 1 -
7 vimala 22 primi - 24 2.2 109 - - - 0 -
8 glory 22 primi - 21.9 3.1 109 - - - 1 -
9 janavi 22 primi - 23 3 112 - - - 0 -
10 sivakami 21 primi - 25 2.2 120 - - - 0 -
11 kanaga 28 multi - 24 4.6 124 - - - 1 -
12 naglini 20 primi both parents DM 21.6 3.6 126 - - - 0 -
13 divya 32 multi - 22 3 128 - - - 0 -
14 udhaya 31 primi - 21.8 3.6 130 - - - 0 -
15 rekha 34 multi - 23.4 3 130 - - - 0 -
16 deepika 21 primi - 21.4 3.6 132 - - - 0 -
17 suriya 22 multi - 22 3.2 132 - - - 0 -
18 buela 21 primi - 23.5 2.9 132 - - - 0 -
19 kalaivani 40 multi - 25 4 132 - - - 0 -
20 geetha 30 primi - 24.5 3.6 132 - - - 1 -
21 raghavi 23 multi - 22 3.2 136 - - - 0 -
22 mahalakshmi 23 multi - 19 3.9 136 - - - 1 -
23 sasikala 22 multi - 19.5 4.1 138 - - - 0 -
24 vanmathi 31 multi - 24 3.3 138 - - - 0 -
25 saranya 21 primi - 23.4 3.7 142 92/168/150/130 0 meal plan
26 meenakshi 21 multi - 21.4 3.1 142 98/190/168/157 0 insulin
27 chitra 28 multi both parents DM 22 2.5 142 78/140/120/110 0 meal plan
28 umadevi 24 multi pre big baby 21.5 4.5 148 90/180/165/140 1 meal plan
29 latha 29 multi TWIN 24 4 148 90 120 1 meal plan
30 ranjith 23 primi - 23.6 3.9 148 92/170/150/140 1 meal plan
31 Aarifa 30 multi - 23.3 3.9 148 70/142/120/110 92 140 0 meal plan
32 prabavathy 26 multi - 24.5 5.6 148 96/182/155/140 92 138 1 meal plan
33 nalini 22 multi - 19 5.6 148 99/185/148/142 1 meal plan
34 valli 22 multi - 19.5 3.7 152 98 176 0 insulin
35 Ramya 23 primi - 23 5.4 152 89/192/159/146 0 meal plan
36 pramila 23 multi - 21 3.9 156 98 114 0 meal plan
37 Thamarai 24 multi - 21.4 3.8 156 90/182/155/140 0 meal plan
38 geetha 28 multi pre GDM 22 3.7 156 94/186/160/110 98 190 0 insulin
39 sasikala 30 multi - 19.8 4 156 96 146 0 meal plan
40 Reeta 35 multi - 23 3.9 156 102 156 0 insulin
41 Ashwini 24 primi - 24 7.1 158 98/182/156/140 1 meal plan
42 pavithra 26 multi - 21.5 4.8 162 146 210 1 insulin
43 Roselin 26 primi pcos 21 4.8 162 98/192/168/140 140 220 1 insulin
44 Dhanalakshmi 34 primi - 23 3.8 162 94/186/172/142 90 112 1 meal plan
MASTER CHART
45 sarojini 22 multi father DM 27.4 2.4 168 146 222 0 insulin
46 Nandhini 30 primi - 23 4.2 168 90/180/170/140 114 170 0 insulin
47 visalatchi 25 multi - 22 5.8 172 90/200/180/154 144 202 1 insulin
48 pavithra 28 multi - 22.1 2.6 96 94/168/16/152 102 142 0 -
49 jeyalakshmi 26 multi - 19 2.2 102 - - - -
50 nivethidha 24 primi - 24.5 3.6 102 - - - 0 -
51 geetha 24 multi - 19.9 3.1 106 - - - 0 -
52 saraswathi 22 multi - 21 2.6 108 - - - 0 -
53 devi 28 primi - 24.3 3.8 108 - - - 0 -
54 sumathi 22 multi - 23 2.2 109 - - - 0 -
55 ponni 27 primi - 21 3.1 109 - - - 1 -
56 dhanam 28 primi - 21.4 3 112 - - - 0 -
57 shanthi 23 multi - 22 2.2 120 - - - 0 -
58 madhavi 22 multi pre big baby 24.4 4.6 124 - - - 1 -
59 chandra 28 primi - 23 3.6 126 - - - 0 -
60 priya 23 primi - 24.2 3 128 - - - 0 -
61 Bakiyalakshmi 28 multi - 23 3.6 130 - - - 0 -
62 Rama 27 multi - 21 3 130 - - - 0 -
63 Rekha 22 multi - 23.5 3.6 132 - - - 0 -
64 prasanna 27 multi - 19.4 3.2 132 - - - 0 -
65 prema 24 primi - 23 2.9 132 - - - 0 -
66 ponniammal 22 multi - 22.6 4 132 - - - 0 -
67 vendam 24 multi - 21.6 3.6 132 - - - 0 -
68 pavithra 29 primi - 22 3.2 136 - - - 0 -
69 pathuvai 25 primi - 21 3.9 136 - - - 0 -
70 mahalakshmi 23 primi - 19.5 4.1 138 - - - 0 -
71 Usha 20 multi - 23 3.3 138 - - - 0 -
72 Durga 19 primi father DM 21.7 3.7 142 88/162/150/130 92 140 0 insulin
73 Devi 24 multi - 22 3.1 142 78/188/58/146 90 108 1 metformin
74 chitra 26 primi - 29.9 2.5 142 89/170/160/132 88 112 0 insulin
75 sudha 21 primi - 23 4.5 148 95/196/74/110 90 110 0 meal plan
76 saraswathi 24 primi - 22 4 148 78/184/160/48 112 148 0 metformin
77 veena 28 multi mother DM 19.7 3.9 148 91/184/150/147 93 125 0 meal plan
78 saranya 32 multi - 23 3.9 148 89/170/160/154 89 114 1 insulin
79 sandhiya 32 multi father DM 22 5.6 148 99/170/162/155 122 176 1 insulin
80 poovizhi 26 multi - 21.8 5.6 148 100/190/170/110 94 126 1 meal plan
81 pavithra 27 primi - 23.4 3.7 152 - 100 132 0 metformin
82 kanchana 35 primi - 22.5 5.4 152 115/272/210/150 160 202 0 insulin
83 pathuvai 26 primi - 19 3.9 156 - 98 143 0 meal plan
84 vani 22 multi - 19.6 3.8 156 - 146 210 0 insulin
85 devi 26 multi pre GDM 23 3.7 156 120/180/168/110 0 meal plan
86 Dhanalakshmi 25 primi - 24.6 4 156 98/164/160/158 98 122 0 meal plan
87 shantha 26 primi - 23 3.9 156 102/160/154/84 90 120 0 meal plan
88 Devi 24 multi - 22.1 7.1 158 - 112 146 0 meal plan
89 ranjani 29 primi - 24 4.8 162 - 87 102 0 meal plan
90 Roshini 25 primi - 21.8 4.8 162 - 134 167 0 insulin
91 lalitha 23 primi - 22 3.8 162 88/162/130/150 88 122 0 meal plan
92 Madhu 20 multi pre GDM 23.9 2.4 168 99/193/150/132 - - 0 insulin
93 Subha 22 multi - 22.6 4.2 168 - 104 142 0 insulin
94 Shanthi 24 primi mother DM 23.3 5.8 172 90/180/160/142 90 122 0 meal plan
95 kanchana 21 primi - 21.4 2.6 96 - - - 1 -
96 kavitha 27 multi - 22 2.2 102 - - - 0 -
97 Fathima 22 multi - 22.1 3.6 102 - - - 0 -
98 Sankari 25 primi - 23 3.1 106 - - - 0 -
99 Usha 26 multi - 22 2.6 108 - - - 0 -
100 Rani 24 multi mother DM 23.1 3.8 108 - - - 0 -
101 Madhumidha 24 primi - 24 2.2 109 - - - 0 -
102 Nancy 38 primi - 24.5 3.1 109 - - - 0 -
103 Supraba 25 primi - 21 3 112 - - - 0 -
104 surya 28 primi - 30.1 2.2 120 - - - 0 -
105 Kavitha rani 22 multi - 22 4.6 124 - - - 0 -
106 Anitha 25 multi - 22.5 3.6 126 - - - 0 -
107 Mariyammal 29 multi - 23 3 128 - - - 0 -
108 Vinarasi 22 multi - 23.4 3.6 130 - - - 0 -
109 Swathi 25 multi - 21 3 130 - - - 0 -
110 Vasanthi 20 primi - 21.4 3.6 132 - - - 1 -
111 Udhaya 25 multi - 21.3 3.2 132 - - - 0 -
112 Vaishnavi 27 multi - 23 2.9 132 - - - 0 -
113 Kanmani 22 multi - 23.4 4 132 - - - 0 -
114 umadevi 27 multi - 22 3.6 132 - - - 0 -
115 Brindha 24 primi - 22.4 3.2 136 - - - 0 -
116 Fathima 22 multi - 21.4 3.9 136 - - - 0 -
117 Anushya 24 multi - 24 4.1 138 - - - 0 -
118 Kalaivani 22 primi - 23 3.3 138 - - - 0 -
119 Kavitha 24 multi - 22.3 3.7 142 98 145 0 metformin
120 Shanthi 36 primi - 21 3.1 142 100/190/140/120 98 108 1 metformin
121 Deepa 28 primi - 21.3 2.5 142 94/168/16/152 1 meal plan
122 Rupadevi 37 primi - 28.9 4.5 148 102 152 1 insulin
123 Usha 22 primi - 24 4 148 90/182/150/130 1 meal plan
124 Latha 24 multi - 24.3 3.9 148 78/188/158/146 0 meal plan
125 Anitha 36 primi - 21.3 3.9 148 98 108 0 metformin
126 Monisha 28 primi - 22 5.6 148 90/178/160/154 0 mealplan
127 Suganya 37 primi - 19 5.6 148 102 152 0 insulin
128 Suguna 25 primi father DM 19.4 3.7 152 94/182/162/145 76 110 0 mealplan
129 Lavanya 21 multi - 18.7 5.4 152 94/156/160/110 0 meal plan
130 Jasmine 25 multi - 23 3.9 156 156 224 0 insulin
131 Udayarani 24 primi - 22 3.8 156 99/188/164/160 0 meal plan
132 Aarthi 24 primi - 21 3.7 156 94/180/160/154 76 98 0 insulin
133 Akila 22 multi - 21.7 4 156 88/162/158/142 0 metformin
134 Saroja 21 multi - 24 3.9 156 146 178 0 insulin
135 Poornima 24 multi - 23 7.1 158 88/170157/150 0 mrtformin
136 Surya 24 primi - 19.4 4.8 162 92/180/162/145 0 mealplan
137 Anandhi 36 primi - 25.6 4.8 162 98/166/154/140 0 mealplan
138 Sundari 20 primi - 24 3.8 162 88 100 0 mealplan
139 Arunthadhi 31 multi - 25 2.4 168 88/160/158/148 80 100 1 mealplan
140 Uma 20 primi - 21.5 4.2 168 99 200 0 insulin
141 Kavya 19 primi - 22 5.8 172 80 114 0 mealplan
142 Vimala 24 multi - 23 2.6 96 - - - 0 -
143 Lavanya 26 multi - 24 2.2 102 - - - 0 -
144 Nancy 28 primi - 23.4 3.6 102 - - - 0 -
145 Nandhini 24 primi - 22.4 3.1 106 - - - 0 -
146 poomika 24 multi - 19 2.6 108 - - - 0 -
147 poonjolai 32 primi - 19.5 3.8 108 - - - 0 -
148 Malliga 24 multi - 21 2.2 109 - - - 0 -
149 thilagam 22 primi - 22.4 3.1 109 - - - 0 -
150 manimegalai 22 primi - 23 3 112 - - - 1 -
151 vinitha 27 multi - 19.8 2.2 120 - - - 0 -
152 prabha 22 primi - 23 4.6 124 - - - 0 -
153 Suganya 22 primi - 21 3.6 126 - - - 0 -
154 sumathi 27 primi - 24.3 3 128 - - - 0 -
155 Bakiyalakshmi 25 multi - 22 3.6 130 - - - 0 -
156 valli 21 primi - 21.4 3 130 - - - 1 -
157 poomika 27 primi - 23.5 3.6 132 - - - 0 -
158 revathy 25 primi - 19 3.2 132 - - - 0 -
159 poomathi 25 multi - 19.6 2.9 132 - - - 0 -
160 Nancy 24 primi - 21 4 132 - - - 0 -
161 vimala 22 multi - 21.3 3.6 132 - - - 1 -
162 vincila 28 multi - 22 3.2 136 - - - 0 -
163 mary 24 multi - 22.5 3.9 136 - - - 0 -
164 nancy stella 24 primi - 24 4.1 138 - - - 0 -
165 Manjula 26 multi - 23.4 3.3 138 - - - 1 -
166 vanaja 25 multi - 21 3.7 142 100/190/158/120 1 meal plan
167 prema 23 multi - 23 3.1 142 96/182/147/99 1 meal plan
168 sarala 23 primi mother DM 22.5 2.5 142 90/180/170/155 100 108 0 mealplan
169 Lakshmi 25 primi - 23.4 4.5 148 98/164/148/120 112 156 0 insulin
170 meenakshi 24 multi - 21 4 148 98/166/154/140 0 meal plan
171 VANI 25 primi - 19 3.9 148 88/160/158/148 92 122 1 insulin
172 Savithri 25 primi - 19.5 3.9 148 97/179/164/159 87 116 0 meal plan
173 bhavani 29 multi - 21.4 5.6 148 110/190/160/130 1 -
174 Bhakya 30 multi - 22 5.6 148 - 99 162 1 insulin
175 Vidhya 27 primi - 31.1 3.7 152 102 166 0 insulin
176 kumari 27 primi - 23 5.4 152 110 153 0 metformin
177 Keerthika 22 primi - 24 3.9 156 96/190/170/90 0 insulin
178 Vasantha 22 primi father DM 21 3.8 156 100/160/154/116 80 106 1 mealplan
179 Manjula 26 primi - 24 3.7 156 94 122 0 insulin
180 Minnala 27 multi - 21 4 156 84/170/160/150 90 110 1 insulin
181 Poorvika 24 multi - 21.8 3.9 156 100/190/150/140 88 118 0 insulin
182 Jasmine 24 multi - 22 7.1 158 90/170/160/150 88 110 0 mealplan
183 janavi 24 multi - 23.5 4.8 162 98/160/140/120 0 mealplan
184 karuthamma 22 primi - 19.7 4.8 162 90/170/158/120 1 mealplan
185 poovizhi 24 primi - 21 3.8 162 92/186/155/132 0
186 Radhika 26 multi - 24.6 2.4 168 96/176/162/143 0 metformin
187 Vimala 25 primi - 23 4.2 168 88/190/160/120 84 98 0 mealplan
188 Vinodhini 23 primi - 23.1 5.8 172 - 94 164 0 insulin
189 Thangam 21 primi - 24 3.9 156 98/160/158/140 84 119 0 mealplan
190 Kani 26 multi - 23 3.8 156 90/185/163/140 - - 1 insulin
191 Dhanasri 24 primi pre big baby 23.5 3.7 156 98/190/166/120 - - 0 insulin
192 Vani 21 primi - 19 4 156 90/182/155/100 - - 0 meal plan
193 Vijaya 27 multi - 21 3.9 156 98/160/158/120 - - 0 mealplan
194 Hemalatha 24 primi - 21.7 7.1 158 - 143 189 0 insulin
195 Kalaivani 23 multi - 25 4.8 162 - 98 156 0 meal plan
196 pommi 24 multi - 28 4.8 162 98/190/168/140 100 148 0 insulin
197 mala 23 primi - 24.5 3.8 162 90 126 1 meal plan
198 Suguna 25 multi - 21 2.4 168 84/182/154/132 102 146 0 meal plan
199 Vanathi 25 multi pre big baby 21.7 4.2 168 86/190/160/124 84 118 1 insulin
200 meenakshi 23 multi - 22 5.8 172 92/178/160/146 88 193 0 insulin
0 = No Pregnancy Induced Hypertension                    1 = Presence of Pregnacy Induced Hypertension
